From: Impairment of endothelial function in Parkinson’s disease
Parkinsonʼs disease | Controls | p-value | |
---|---|---|---|
Number of subjects | 41 | 41 | |
Male/female sex | 24/17 (58.5%/41.5%) | 24/17 (58.5%/41.5%) | 1.0 |
Age (years) | 65.4 ± 9.1 | 65.3 ± 10.7 | 0.947 |
BMI (kg/m2) | 27.5 ± 4.8 | 27.5 ± 3.6 | 0.996 |
Arterial hypertension | 20 (48.8%) | 21 (51.2%) | 0.825 |
Coronary heart disease | 6 (14.6%) | 6 (14.6%) | 1.0 |
Diabetes mellitus | 8 (19.5%) | 7 (17.1%) | 0.775 |
Dyslipidaemia | 6 (14.6%) | 8 (19.5%) | 0.557 |
Smoking | 6 (14.6%) | 6 (14.6%) | 1.0 |
RHI | 1.8 ± 0.5 | 1.9 ± 0.5 | 0.478 |
Endothelial dysfunction | 19 (46.3%) | 14 (34.1%) | 0.260 |
Hoehn and Yahr score | 0, 2.5 (0–4.0) | – | – |
Duration of PD since diagnosis (years) | 0, 5.0 (0–15.0) | – | – |
LED (mg) | 900.0 (0–2280.0) | – | – |
L-dopa | 31 (75.6) | – | – |
Dopamine agonists | 25 (61%) | – | – |
COMT inhibitors | 18 (43.9) | – | – |
MAO-B inhibitors | 14 (34.1) | – | – |
Amantadine | 6 (14.6%) | – | – |